Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947993 · ClinicalTrials.gov registry record · Phase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 20
- Study locations
NCT06947993: Recruiting Phase 2 study of Atopic Dermatitis, sponsored by Novartis Pharmaceuticals.
NCT06947993 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 224 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06947993, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Primary Outcome
EASI will be used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GHZ339
Study Locations (20)
California
- Novartis Investigative Site - Fountain Valley
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - Santa Ana
- Novartis Investigative Site - Santa Monica
Texas
- Novartis Investigative Site - Arlington
- Novartis Investigative Site - Cypress
- Novartis Investigative Site - Dallas
Alabama
- Novartis Investigative Site - Birmingham
- Novartis Investigative Site - Birmingham
Georgia
- Novartis Investigative Site - Atlanta
- Novartis Investigative Site - Macon
Arkansas
- Novartis Investigative Site - Fort Smith
District of Columbia
- Novartis Investigative Site - Washington D.C.
Florida
- Novartis Investigative Site - Miami
Kentucky
- Novartis Investigative Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2028-12-22 |
| Phase | Phase 2 |
What NCT06947993 shows while recruiting
NCT06947993 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06947993 names 20 study sites across 12 states, led by California, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT06947993 about?
NCT06947993 is a clinical study titled "Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis". This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT06947993?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2025-05-16. Estimated completion is 2028-12-22.
What conditions does trial NCT06947993 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06947993?
The interventions under investigation include: Placebo (DRUG), GHZ339 (DRUG).
Who is sponsoring clinical trial NCT06947993?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947993 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06947993's enrollment target sits among peer trials
224 51st of 150 higher than 100 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI